CA2409752A1 - Single copy genomic hybridization probes and method of generating same - Google Patents
Single copy genomic hybridization probes and method of generating same Download PDFInfo
- Publication number
- CA2409752A1 CA2409752A1 CA002409752A CA2409752A CA2409752A1 CA 2409752 A1 CA2409752 A1 CA 2409752A1 CA 002409752 A CA002409752 A CA 002409752A CA 2409752 A CA2409752 A CA 2409752A CA 2409752 A1 CA2409752 A1 CA 2409752A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- probe
- nucleic acid
- probes
- single copy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000523 sample Substances 0.000 title claims abstract description 334
- 238000009396 hybridization Methods 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims abstract description 92
- 108020004414 DNA Proteins 0.000 claims abstract description 77
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 69
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 50
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 50
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 30
- 238000002372 labelling Methods 0.000 claims abstract description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 47
- 239000002773 nucleotide Substances 0.000 claims description 45
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims description 35
- 230000002759 chromosomal effect Effects 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000000295 complement effect Effects 0.000 claims description 22
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 20
- 239000002853 nucleic acid probe Substances 0.000 claims description 20
- 239000011541 reaction mixture Substances 0.000 claims description 16
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000000903 blocking effect Effects 0.000 claims description 9
- 238000007901 in situ hybridization Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 5
- -1 antibodies Proteins 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 238000002105 Southern blotting Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 208000035970 Chromosome Breakpoints Diseases 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 abstract description 84
- 239000012634 fragment Substances 0.000 abstract description 34
- 238000001514 detection method Methods 0.000 abstract description 19
- 238000004458 analytical method Methods 0.000 abstract description 12
- 238000012408 PCR amplification Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 208000031404 Chromosome Aberrations Diseases 0.000 abstract description 5
- 230000029087 digestion Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 206010008805 Chromosomal abnormalities Diseases 0.000 abstract description 2
- 108060002716 Exonuclease Proteins 0.000 abstract description 2
- 102000013165 exonuclease Human genes 0.000 abstract description 2
- 210000000349 chromosome Anatomy 0.000 description 127
- 239000013615 primer Substances 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 20
- 238000012217 deletion Methods 0.000 description 20
- 230000037430 deletion Effects 0.000 description 20
- 230000031864 metaphase Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
- 238000000137 annealing Methods 0.000 description 14
- 230000005945 translocation Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000003298 DNA probe Substances 0.000 description 11
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 11
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 9
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 9
- 102100030473 Protein HIRA Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 8
- 101000842368 Homo sapiens Protein HIRA Proteins 0.000 description 8
- 238000004925 denaturation Methods 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108091035233 repetitive DNA sequence Proteins 0.000 description 8
- 102000053632 repetitive DNA sequence Human genes 0.000 description 8
- 208000026350 Inborn Genetic disease Diseases 0.000 description 7
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 7
- 238000004590 computer program Methods 0.000 description 7
- 230000002559 cytogenic effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 208000016361 genetic disease Diseases 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 230000008707 rearrangement Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 101150049556 Bcr gene Proteins 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 208000037516 chromosome inversion disease Diseases 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101100268645 Caenorhabditis elegans abl-1 gene Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 201000000866 velocardiofacial syndrome Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091060290 Chromatid Proteins 0.000 description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 4
- 101100268646 Homo sapiens ABL1 gene Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004756 chromatid Anatomy 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 230000008711 chromosomal rearrangement Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 101150027973 hira gene Proteins 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108091023043 Alu Element Proteins 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 2
- 208000004860 Blast Crisis Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101000738400 Homo sapiens Cyclin-dependent kinase 11B Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000012268 genome sequencing Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108090000771 necdin Proteins 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 description 1
- 101150073635 Ass gene Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000014392 Cat-eye syndrome Diseases 0.000 description 1
- 208000016718 Chromosome Inversion Diseases 0.000 description 1
- 102100037916 Cyclin-dependent kinase 11B Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101100017050 Homo sapiens HIRA gene Proteins 0.000 description 1
- 101100512259 Homo sapiens MAGEL2 gene Proteins 0.000 description 1
- 101001133624 Homo sapiens Polyadenylate-binding protein-interacting protein 1 Proteins 0.000 description 1
- 101001120872 Homo sapiens Probable E3 ubiquitin-protein ligase makorin-3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101150042280 MAGEL2 gene Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 229910017917 NH4 Cl Inorganic materials 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102100026051 Probable E3 ubiquitin-protein ligase makorin-3 Human genes 0.000 description 1
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 1
- 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101150008534 Shmt1 gene Proteins 0.000 description 1
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical class CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 101150061397 cnfn gene Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000661 isochromosome Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229940096405 magnesium cation Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- XGEGHDBEHXKFPX-NJFSPNSNSA-N methylurea Chemical compound [14CH3]NC(N)=O XGEGHDBEHXKFPX-NJFSPNSNSA-N 0.000 description 1
- 208000030454 monosomy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 102000004212 necdin Human genes 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/573,080 | 2000-05-16 | ||
| US09/573,080 US6828097B1 (en) | 2000-05-16 | 2000-05-16 | Single copy genomic hybridization probes and method of generating same |
| US09/854,867 | 2001-05-14 | ||
| US09/854,867 US7014997B2 (en) | 2000-05-16 | 2001-05-14 | Chromosome structural abnormality localization with single copy probes |
| PCT/US2001/015674 WO2001088089A2 (en) | 2000-05-16 | 2001-05-15 | Single copy genomic hybridization probes and method of generating same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2409752A1 true CA2409752A1 (en) | 2001-11-22 |
Family
ID=27076021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002409752A Abandoned CA2409752A1 (en) | 2000-05-16 | 2001-05-15 | Single copy genomic hybridization probes and method of generating same |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20080085509A1 (https=) |
| EP (1) | EP1285093A4 (https=) |
| JP (1) | JP2004523201A (https=) |
| AU (2) | AU2001264610B2 (https=) |
| CA (1) | CA2409752A1 (https=) |
| IL (1) | IL152727A0 (https=) |
| NZ (2) | NZ522406A (https=) |
| WO (1) | WO2001088089A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828097B1 (en) | 2000-05-16 | 2004-12-07 | The Childrens Mercy Hospital | Single copy genomic hybridization probes and method of generating same |
| US7081339B2 (en) * | 2002-04-12 | 2006-07-25 | Primera Biosystems, Inc. | Methods for variation detection |
| KR20050073466A (ko) * | 2002-09-30 | 2005-07-13 | 칠드런스 머시 호스피탈 | 서브텔로미어 디엔에이 프로브 및 이의 제조 방법 |
| GB0326197D0 (en) * | 2003-11-10 | 2003-12-17 | Randox Lab Ltd | Molecular marker |
| US20080044916A1 (en) * | 2004-03-26 | 2008-02-21 | Rogan Peter K | Computational selection of probes for localizing chromosome breakpoints |
| US20060223075A1 (en) * | 2005-03-29 | 2006-10-05 | Exagen Diagnostics, Inc. | Unique sequence hybridization probes (USP) |
| US8407013B2 (en) | 2005-06-07 | 2013-03-26 | Peter K. Rogan | AB initio generation of single copy genomic probes |
| US7734424B1 (en) | 2005-06-07 | 2010-06-08 | Rogan Peter K | Ab initio generation of single copy genomic probes |
| JP2009518004A (ja) * | 2005-11-18 | 2009-05-07 | ザ チルドレンズ マーシー ホスピタル | 核酸ハイブリダイゼーションにおけるＣｏｔ−１ＤＮＡの歪みの低減 |
| ES2372427T3 (es) * | 2006-09-01 | 2012-01-19 | Ventana Medical Systems, Inc. | Método para producir sondas de ácido nucleico. |
| DK2444807T3 (da) | 2006-11-01 | 2014-08-11 | Ventana Med Syst Inc | Mono- og dinitropyrazolhaptenkonjugater |
| WO2008119084A1 (en) * | 2007-03-28 | 2008-10-02 | The Children's Mercy Hospital | Method for identifying and selecting low copy nucleic acid segments |
| US7682789B2 (en) | 2007-05-04 | 2010-03-23 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| WO2009149013A2 (en) | 2008-06-05 | 2009-12-10 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
| NZ600375A (en) | 2009-11-23 | 2014-10-31 | Bayer Cropscience Nv | Herbicide tolerant soybean plants and methods for identifying same |
| PH12012501096A1 (en) | 2009-11-23 | 2012-10-29 | BASF Agricultural Solutions Seed US LLC | Elite event ee-gm3 and methods and kits for identifying such event in biological samples |
| CA2780827A1 (en) * | 2009-12-31 | 2011-07-07 | Ventana Medical Systems, Inc. | Methods for producing uniquely specific nucleic acid probes |
| JP2017533733A (ja) * | 2014-11-11 | 2017-11-16 | アボツト・モレキユラー・インコーポレイテツド | ハイブリダイゼーションプローブおよび方法 |
| US11371087B2 (en) * | 2016-06-10 | 2022-06-28 | Takara Bio Usa, Inc. | Methods and compositions employing blocked primers |
| US20230183780A1 (en) | 2016-07-25 | 2023-06-15 | InVivo BioTech Services GmbH | Dna probes for in situ hybridization on chromosomes |
| EP4556575A3 (en) | 2016-11-21 | 2025-10-08 | Bruker Spatial Biology, Inc. | A method for sequencing nucleic acids |
| EP3794146B1 (en) | 2018-05-14 | 2025-12-10 | Bruker Spatial Biology, Inc. | Method for identifying a predetermined nucleotide sequence |
| EP3940075A1 (en) * | 2020-07-17 | 2022-01-19 | Istituto Nazionale Di Genetica Molecolare-INGM | Inhibitors of line1 and uses thereof |
| CN113483931B (zh) * | 2021-07-02 | 2023-01-24 | 中国国家铁路集团有限公司 | 弓网接触力区段异常识别方法及装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110920A (en) | 1982-01-22 | 1992-05-05 | Cetus Corporation | HLA typing method and DNA probes used therein |
| US5985549A (en) | 1985-10-22 | 1999-11-16 | University Of Massachusetts | Non-isotopic in-situ hybridization method for detection of nucleic acids |
| US5721098A (en) * | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US5756696A (en) * | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
| US5273881A (en) | 1990-05-07 | 1993-12-28 | Daikin Industries, Ltd. | Diagnostic applications of double D-loop formation |
| US6040140A (en) * | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
| US6121419A (en) * | 1992-06-17 | 2000-09-19 | Arch Development Corp. | Compositions and methods for detecting gene rearrangements and translocations |
| HK1004920A1 (en) * | 1993-01-21 | 1998-12-11 | President And Fellows Of Harvard College | Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound |
| US6150160A (en) * | 1995-11-16 | 2000-11-21 | The John Hopkins University | Compositions and methods of use of mammalian retrotransposons |
| US6222029B1 (en) * | 1997-08-01 | 2001-04-24 | Genset | 5′ ESTs for secreted proteins expressed in brain |
| US6828097B1 (en) * | 2000-05-16 | 2004-12-07 | The Childrens Mercy Hospital | Single copy genomic hybridization probes and method of generating same |
| US7585964B2 (en) * | 2001-05-14 | 2009-09-08 | Cancer Genetics, Inc. | Methods of analyzing chromosomal translocations using fluorescence in situ hybridization (FISH) |
-
2001
- 2001-05-15 JP JP2001585298A patent/JP2004523201A/ja active Pending
- 2001-05-15 IL IL15272701A patent/IL152727A0/xx unknown
- 2001-05-15 CA CA002409752A patent/CA2409752A1/en not_active Abandoned
- 2001-05-15 AU AU2001264610A patent/AU2001264610B2/en not_active Ceased
- 2001-05-15 NZ NZ522406A patent/NZ522406A/xx unknown
- 2001-05-15 WO PCT/US2001/015674 patent/WO2001088089A2/en not_active Ceased
- 2001-05-15 EP EP01939048A patent/EP1285093A4/en not_active Withdrawn
- 2001-05-15 NZ NZ539223A patent/NZ539223A/en unknown
- 2001-05-15 AU AU6461001A patent/AU6461001A/xx active Pending
-
2004
- 2004-06-23 US US10/876,297 patent/US20080085509A1/en not_active Abandoned
-
2009
- 2009-03-25 US US12/411,359 patent/US20090312533A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001264610B2 (en) | 2007-01-04 |
| IL152727A0 (en) | 2003-06-24 |
| NZ539223A (en) | 2006-10-27 |
| WO2001088089A8 (en) | 2005-04-07 |
| US20080085509A1 (en) | 2008-04-10 |
| EP1285093A4 (en) | 2005-10-12 |
| WO2001088089A3 (en) | 2002-07-04 |
| JP2004523201A (ja) | 2004-08-05 |
| NZ522406A (en) | 2006-05-26 |
| US20090312533A1 (en) | 2009-12-17 |
| WO2001088089A2 (en) | 2001-11-22 |
| AU6461001A (en) | 2001-11-26 |
| EP1285093A2 (en) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7014997B2 (en) | Chromosome structural abnormality localization with single copy probes | |
| US20090312533A1 (en) | Single copy genomic hybridization probes and method of generating same | |
| AU2001264610A1 (en) | Single copy genomic hybridization probes and method of generating same | |
| EP1941050B1 (en) | Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes | |
| JPH10506267A (ja) | 核酸の配列または遺伝的変化のハイスループットスクリーニング法 | |
| EP0648222B1 (en) | Methods of single nucleotide primer extension to detect specific alleles and kits therefor | |
| JP2015508995A (ja) | 核酸ハイブリダイゼーションプローブ | |
| CN101294222A (zh) | 用于检测血清淀粉状蛋白a1(saa1)的基因型的核苷酸引物组和核苷酸探针 | |
| CN102112628A (zh) | 先天性异常症的染色体缺失的检测方法 | |
| US20230183780A1 (en) | Dna probes for in situ hybridization on chromosomes | |
| CN103649332A (zh) | 用于β地中海贫血性状的新型相关标记 | |
| JP2001505428A (ja) | 染色体異常の検出 | |
| JP2011528554A (ja) | 母親の全血からの非侵襲的胎児ＲｈＤジェノタイピング | |
| EP1846760B1 (en) | Rapid comparative genome hybridization | |
| WO1998023778A1 (en) | A RAPID METHOD FOR DIAGNOSING THE VARIOUS FORMS OF α-THALASSEMIA | |
| EP2453022A1 (en) | Method for detection or analysis of target sequence in genomic dna | |
| CN113957158B (zh) | 一种用于检测施氏鲟线粒体基因的引物探针组合物、试剂盒及其应用 | |
| CN114645079B (zh) | 一种检测孕妇样品中胎儿游离dna存在或比例的方法和试剂盒 | |
| JP3623495B2 (ja) | キメラ遺伝子の検出方法 | |
| EP4731782A1 (en) | Interlocking nucleic acids for target hybridization | |
| JP2010124823A (ja) | 肥満遺伝子の遺伝子多型をタイピングするプライマーおよい競合プローブ | |
| Poulsen et al. | Situ Hybridization (FISH) | |
| JP2010200675A (ja) | 精神遅滞を伴う多発性奇形症候群の判別方法 | |
| IL106199A (en) | Method of single nucleotide prime extension to detect specific alleles and kit therefor | |
| HK1123072A (en) | Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140515 |